Download PDF

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update

  • An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto
  • Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA
  • Both Phase 3 ROLONTIS® (eflapegrastim) studies, RECOVER and ADVANCE, have met the primary efficacy endpoint; Spectrum is preparing for a pre-BLA meeting with the FDA in the third quarter
  • Q2 revenues were $24.2 million, including $23.8 million in product sales

HENDERSON, Nev.--(BUSINESS WIRE)--Aug. 9, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended June 30, 2018.

“The second quarter marked significant progress and data milestones for our two lead programs poziotinib and ROLONTIS, moving us closer to our ultimate goal of delivering targeted and novel therapies to cancer patients,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. “We have strong momentum going into the second half of the year as we aggressively broaden our poziotinib clinical program and continue to gain additional regulatory clarity.”

Clinical Program Overview:

Poziotinib, an irreversible tyrosine kinase inhibitor targeting EGFR and HER2 mutations:

  • Updated data from the MD Anderson Phase 2 trial in non-small cell lung cancer with exon 20 mutations will be presented at the World Conference on Lung Cancer in Toronto on September 24. Updated data will include EGFR and HER2 patients with exon 20 mutations. The abstract will be released online on September 5.
  • Spectrum recently had a meeting with the FDA regarding poziotinib to gain clarity on the regulatory pathway. Based on that conversation, Spectrum views the current poziotinib phase 2 study as the pivotal registrational trial needed for the Agency’s review.
  • Data published in Nature Medicine from the first 11 NSCLC patients with EGFR exon 20 mutations receiving poziotinib in MD Anderson’s Phase 2 clinical trial demonstrated a confirmed objective response rate of 64 percent. The median progression-free survival had not been reached, with a median follow up of 6.6 months. The safety profile was consistent with what has been previously described for poziotinib and other TKIs with the two most common adverse events being known EGFR inhibitor-related toxicities: skin rash and diarrhea.
  • Data presented at AACR demonstrated that HER2 exon 20 mutations were prevalent across multiple solid tumors.

ROLONTIS (eflapegrastim), a novel long-acting GCSF:

  • Spectrum plans to conduct a pre-BLA meeting in the third quarter to ensure alignment with the FDA in preparation for a planned BLA filing in the fourth quarter of 2018.
  • Top line data from RECOVER, the second Phase 3 ROLONTIS study, demonstrated that the study met the primary efficacy endpoint of non-inferiority in the duration of severe neutropenia (DSN) between ROLONTIS and pegfilgrastim. Both Phase 3 ROLONTIS clinical trials, ADVANCE and RECOVER which studied more than 600 patients combined, have met the primary efficacy endpoint. Additional RECOVER data will be released at a future medical meeting.
  • ADVANCE data released as part of ASCO 2018 demonstrated that ROLONTIS was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. Mean DSN±SD was 0.19±0.478 days for ROLONTIS and 0.34±0.668 days for pegfilgrastim, demonstrating non-inferiority with 95 percent confidence interval (CI) of DSN: [-0.260, -0.035]; p<0.0001) in Cycle 1. There were no statistically significant differences in all secondary endpoints in Cycle 1. The adverse event profiles were similar across groups. The most common treatment emergent adverse events in both treatment arms were fatigue, nausea, neutropenia, and lymphopenia.
  • In an oral presentation at MASCC 2018, data from the ADVANCE Phase 3 study demonstrated an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1. Absolute risk reduction was defined as the difference in percentage of patients experiencing no severe neutropenia (ROLONTIS 84.2 percent; pegfilgrastim 75.7 percent).

Financial Guidance

Spectrum’s 2018 revenue guidance remains between $95 to $115 million. Additionally, Spectrum anticipates current cash and marketable securities will be sufficient to fund operations into 2020.

Three-Month Period Ended June 30, 2018 (All numbers are approximate)

GAAP Results

Total product sales were $23.8 million in the second quarter of 2018. Product sales in the second quarter included: FOLOTYN® (pralatrexate injection) net sales of $11.7 million, EVOMELA® (melphalan) for injection net sales of $5.8 million, BELEODAQ® (belinostat) for injection net sales of $2.7 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $1.6 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $1.1 million, and FUSILEV® (levoleucovorin) net sales of $0.8 million.

Spectrum recorded net income of $13.7 million, or $0.13 income per basic share and $0.13 per diluted share in the three-month period ended June 30, 2018, compared to net loss of $(20.9) million, or $(0.27) loss per basic and diluted share in the comparable period in 2017. Total research and development expenses were $21.5 million in the quarter, as compared to $15.2 million in the same period in 2017. Selling, general and administrative expenses were $23.5 million in the quarter, compared to $17.4 million in the same period in 2017.

Non-GAAP Results

Spectrum recorded non-GAAP net loss of $(21.6) million, or $(0.21) loss per basic and diluted share in the three-month period ended June 30, 2018, compared to non-GAAP net loss of $(8.6) million, or $(0.11) loss per basic and diluted share in the comparable period in 2017. Non-GAAP research and development expenses were $20.1 million, as compared to $14.6 million in the same period of 2017. Non-GAAP selling, general and administrative expenses were $19.6 million, as compared to $14.5 million in the same period in 2017.

Conference Call

Thursday, August 9, 2018 @ 4:30 p.m. Eastern/1:30 p.m. Pacific


(877) 837-3910

        Conference ID# 9084737

(973) 796-5077

Conference ID# 9084737

This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: on August 9, 2018 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially.These statements are based on management's current beliefs and expectations.These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact.Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission.The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, BELEODAQ®, EVOMELA®, and ROLONTIS®are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates.REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc.Any other trademarks are the property of their respective owners.

© 2018 Spectrum Pharmaceuticals, Inc.All Rights Reserved

Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
  Three Months Ended   Six Months Ended
June 30, June 30,
  2018       2017     2018       2017  
Product sales, net $ 23,753 $ 31,156 $ 51,863 $ 57,001
License fees and service revenue   415     3,145     2,799     6,401  
Total revenues $ 24,168   $ 34,301   $ 54,662   $ 63,402  
Operating costs and expenses:
Cost of sales (excludes amortization of intangible assets) 6,606 11,303 13,420 19,439
Cost of service revenue 2,118 4,221
Selling, general and administrative 23,451 17,421 47,556 36,525
Research and development 21,488 15,167 39,382 29,945
Amortization of intangible assets   6,934     6,901     13,880     13,790  
Total operating costs and expenses   58,479     52,910     114,238     103,920  
Loss from operations   (34,311 )   (18,609 )   (59,576 )   (40,518 )
Other income (expense):
Interest expense, net (242 ) (2,131 ) (472 ) (4,182 )
Change in fair value of contingent consideration related to acquisitions (192 ) (97 ) (483 ) (294 )
Other income, net   48,492     240     58,463     650  
Total other income (expense)   48,058     (1,988 )   57,508     (3,826 )
Income (loss) before income taxes 13,747 (20,597 ) (2,068 ) (44,344 )
Provision for income taxes   (3 )   (255 )   (6 )   (54 )
Net income (loss) $ 13,744   $ (20,852 ) $ (2,074 ) $ (44,398 )
Net income (loss) per share:
Basic $ 0.13   $ (0.27 ) $ (0.02 ) $ (0.57 )
Diluted $ 0.13   $ (0.27 ) $ (0.02 ) $ (0.57 )
Weighted average shares outstanding:
Basic   102,597,059     78,576,260     101,747,416     78,366,610  
Diluted   112,617,150     78,576,260     101,747,416     78,366,610  
Condensed Consolidated Balance Sheets
(In thousands, expect per share and par value amounts)
  June 30,   December 31,
  2018     2017  
Current assets:
Cash and cash equivalents $ 174,371 $ 227,323
Marketable securities 95,287 248
Accounts receivable, net of allowance for doubtful accounts of $70 and $71, respectively 27,658 32,260
Other receivables 2,915 2,133
Inventories 4,520 5,715
Prepaid expenses and other assets   4,769     10,067  
Total current assets 309,520 277,746
Property and equipment, net of accumulated depreciation 523 589
Intangible assets, net of accumulated amortization 123,214 137,159
Goodwill 18,106 18,162
Other assets   13,159     53,783  
Total assets $ 464,522   $ 487,439  
Current liabilities:
Accounts payable and other accrued liabilities $ 49,886 $ 58,117
Accrued payroll and benefits 4,946 9,261
Deferred revenue 3,872
FOLOTYN development liability 211 275
Convertible senior notes   39,427     38,224  
Total current liabilities 94,470 109,749
FOLOTYN development liability, less current portion 11,980 12,111
Deferred revenue, less current portion 315
Acquisition-related contingent obligations 6,755 6,272
Deferred tax liabilities 1,447 1,438
Other long-term liabilities   5,751     6,215  
Total liabilities 120,403 136,100
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 105,130,603 and 100,742,735 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 103 100
Additional paid-in capital 829,052 837,347
Accumulated other comprehensive (loss) income (3,088 ) 15,999
Accumulated deficit   (481,948 )   (502,107 )
Total stockholders’ equity   344,119     351,339  
Total liabilities and stockholders’ equity $ 464,522   $ 487,439  

Non-GAAP Financial Measures

In this press release, Spectrum reports certain historical and expected non-GAAP results. Non-GAAP financial measures are reconciled to the most directly comparable GAAP financial measure in the tables of this press release and the accompanying footnotes. The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items summarized in the below table. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the company's on-going core operating performance.

Management uses non-GAAP net income (loss) in its evaluation of the company's core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that providing these non-GAAP financial measures allows investors to view the company's financial results in the way that management views the financial results.

The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the company's business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the company may be different from the non-GAAP financial measures used by other companies.

Reconciliation of Non-GAAP Adjustments for Condensed Consolidated Statements of Operations

(In thousands, expect per share amounts)

    Three Months Ended   Six Months Ended
June 30, June 30,
  2018       2017